CIK 0001124140
EXAS EXACT SCIENCES CORP
Insider trading from SEC Form 4. Last filing Mar 10, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Signals
Open-market buys and sells at EXACT SCIENCES CORP, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Kevin T Conroy President and CEO buy | $1.0M 19,500 shares | +2% | - |
Congressional trades
1 trade in EXAS disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Kevin Hern House · R-OK | Sale | EXAS Exact Sciences Corporation - Common Stock | $1,001 to $15k | Mar 24 / Apr 3 10 days after the trade | Clerk |
Transactions
The last 93 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 7, 2025 | Kevin T Conroy President and CEO | MOption exercise Common Stock | +66,723 | $22.38 | $1.5M | 1,203,269 | Mar 10, 2025 |
| Mar 7, 2025 | Kevin T Conroy President and CEO | FTax withholding Common Stock | -48,929 | $47.06 | $2.3M | 1,154,340 | Mar 10, 2025 |
| Mar 7, 2025 | Kevin T Conroy President and CEO | MOption exercise Stock Options (Right to Buy)derivative | -66,723 | $0.00 | $0 | 0 | Mar 10, 2025 |
| Feb 28, 2025 | Jacob A Orville EVP, GM, Screening | MOption exercise Common Stock | +4,725 | $0.00 | $0 | 25,001 | Mar 4, 2025 |
| Feb 28, 2025 | Kevin T Conroy President and CEO | MOption exercise Common Stock | +18,143 | $0.00 | $0 | 1,133,326 | Mar 4, 2025 |
| Feb 28, 2025 | James Herriott SVP, General Counsel & Sec | MOption exercise Common Stock | +1,890 | $0.00 | $0 | 14,853 | Mar 4, 2025 |
| Feb 28, 2025 | Sarah Condella EVP, Human Resources | MOption exercise Common Stock10b5-1 | +3,780 | $0.00 | $0 | 82,218 | Mar 4, 2025 |
| Feb 28, 2025 | Brian Baranick EVP, GM, Precision Oncology | MOption exercise Common Stock | +4,725 | $0.00 | $0 | 22,558 | Mar 4, 2025 |
| Feb 28, 2025 | James Herriott SVP, General Counsel & Sec | FTax withholding Common Stock | -889 | $47.82 | $43k | 13,964 | Mar 4, 2025 |
| Feb 28, 2025 | Sarah Condella EVP, Human Resources | FTax withholding Common Stock10b5-1 | -1,777 | $47.82 | $85k | 80,441 | Mar 4, 2025 |
| Feb 28, 2025 | Brian Baranick EVP, GM, Precision Oncology | FTax withholding Common Stock | -2,400 | $47.82 | $115k | 20,158 | Mar 4, 2025 |
| Feb 28, 2025 | Kevin T Conroy President and CEO | FTax withholding Common Stock | -8,528 | $47.82 | $408k | 1,124,798 | Mar 4, 2025 |
| Feb 28, 2025 | Jacob A Orville EVP, GM, Screening | FTax withholding Common Stock | -2,221 | $47.82 | $106k | 22,780 | Mar 4, 2025 |
| Feb 28, 2025 | James Herriott SVP, General Counsel & Sec | MOption exercise Common Stock | +2,375 | $0.00 | $0 | 16,339 | Mar 4, 2025 |
| Feb 28, 2025 | Brian Baranick EVP, GM, Precision Oncology | MOption exercise Common Stock | +4,948 | $0.00 | $0 | 25,106 | Mar 4, 2025 |
| Feb 28, 2025 | Sarah Condella EVP, Human Resources | MOption exercise Common Stock10b5-1 | +3,958 | $0.00 | $0 | 84,399 | Mar 4, 2025 |
| Feb 28, 2025 | Jacob A Orville EVP, GM, Screening | MOption exercise Common Stock | +4,948 | $0.00 | $0 | 27,728 | Mar 4, 2025 |
| Feb 28, 2025 | Kevin T Conroy President and CEO | MOption exercise Common Stock | +22,167 | $0.00 | $0 | 1,146,965 | Mar 4, 2025 |
| Feb 28, 2025 | James Herriott SVP, General Counsel & Sec | FTax withholding Common Stock | -1,117 | $47.82 | $53k | 15,222 | Mar 4, 2025 |
| Feb 28, 2025 | Jacob A Orville EVP, GM, Screening | FTax withholding Common Stock | -2,326 | $47.82 | $111k | 25,402 | Mar 4, 2025 |
| Feb 28, 2025 | Kevin T Conroy President and CEO | FTax withholding Common Stock | -10,419 | $47.82 | $498k | 1,136,546 | Mar 4, 2025 |
| Feb 28, 2025 | Sarah Condella EVP, Human Resources | FTax withholding Common Stock10b5-1 | -1,861 | $47.82 | $89k | 82,538 | Mar 4, 2025 |
| Feb 28, 2025 | Brian Baranick EVP, GM, Precision Oncology | FTax withholding Common Stock | -2,513 | $47.82 | $120k | 22,593 | Mar 4, 2025 |
| Mar 3, 2025 | Sarah Condella EVP, Human Resources | GGift Common Stock10b5-1 | -1,055 | $0.00 | $0 | 81,483 | Mar 4, 2025 |
| Feb 28, 2025 | Jacob A Orville EVP, GM, Screening | MOption exercise Restricted Stock Unitsderivative | -4,725 | $0.00 | $0 | 9,450 | Mar 4, 2025 |
| Feb 28, 2025 | Brian Baranick EVP, GM, Precision Oncology | MOption exercise Restricted Stock Unitsderivative | -4,725 | $0.00 | $0 | 9,450 | Mar 4, 2025 |
| Feb 28, 2025 | James Herriott SVP, General Counsel & Sec | MOption exercise Restricted Stock Unitsderivative | -1,890 | $0.00 | $0 | 3,780 | Mar 4, 2025 |
| Feb 28, 2025 | James Herriott SVP, General Counsel & Sec | MOption exercise Restricted Stock Unitsderivative | -2,375 | $0.00 | $0 | 7,125 | Mar 4, 2025 |
| Feb 28, 2025 | Sarah Condella EVP, Human Resources | MOption exercise Restricted Stock Unitsderivative10b5-1 | -3,780 | $0.00 | $0 | 7,560 | Mar 4, 2025 |
| Feb 28, 2025 | Jacob A Orville EVP, GM, Screening | MOption exercise Restricted Stock Unitsderivative | -4,948 | $0.00 | $0 | 14,845 | Mar 4, 2025 |
| Feb 28, 2025 | Brian Baranick EVP, GM, Precision Oncology | MOption exercise Restricted Stock Unitsderivative | -4,948 | $0.00 | $0 | 14,845 | Mar 4, 2025 |
| Feb 28, 2025 | Sarah Condella EVP, Human Resources | MOption exercise Restricted Stock Unitsderivative10b5-1 | -3,958 | $0.00 | $0 | 11,876 | Mar 4, 2025 |
| Feb 28, 2025 | Kevin T Conroy President and CEO | MOption exercise Restricted Stock Unitsderivative | -18,143 | $0.00 | $0 | 36,286 | Mar 4, 2025 |
| Feb 28, 2025 | Kevin T Conroy President and CEO | MOption exercise Restricted Stock Unitsderivative | -22,167 | $0.00 | $0 | 66,504 | Mar 4, 2025 |
| Feb 25, 2025 | James Herriott SVP, General Counsel & Sec | MOption exercise Common Stock | +1,647 | $0.00 | $0 | 13,738 | Feb 26, 2025 |
| Feb 24, 2025 | Aaron Bloomer EVP, Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +28,779 | $0.00 | $0 | 28,779 | Feb 26, 2025 |
| Feb 25, 2025 | Jacob A Orville EVP, GM, Screening | MOption exercise Common Stock | +3,954 | $0.00 | $0 | 22,136 | Feb 26, 2025 |
| Feb 25, 2025 | Kevin T Conroy President and CEO | MOption exercise Common Stock | +13,180 | $0.00 | $0 | 1,121,378 | Feb 26, 2025 |
| Feb 25, 2025 | Sarah Condella EVP, Human Resources | MOption exercise Common Stock | +3,954 | $0.00 | $0 | 80,297 | Feb 26, 2025 |
| Feb 25, 2025 | Brian Baranick EVP, GM, Precision Oncology | MOption exercise Common Stock | +3,954 | $0.00 | $0 | 19,841 | Feb 26, 2025 |
| Feb 25, 2025 | Sarah Condella EVP, Human Resources | FTax withholding Common Stock | -1,859 | $51.28 | $95k | 78,438 | Feb 26, 2025 |
| Feb 25, 2025 | Kevin T Conroy President and CEO | FTax withholding Common Stock | -6,195 | $51.28 | $318k | 1,115,183 | Feb 26, 2025 |
| Feb 25, 2025 | Jacob A Orville EVP, GM, Screening | FTax withholding Common Stock | -1,859 | $51.28 | $95k | 20,277 | Feb 26, 2025 |
| Feb 25, 2025 | Brian Baranick EVP, GM, Precision Oncology | FTax withholding Common Stock | -2,008 | $51.28 | $103k | 17,833 | Feb 26, 2025 |
| Feb 25, 2025 | James Herriott SVP, General Counsel & Sec | FTax withholding Common Stock | -775 | $51.28 | $40k | 12,963 | Feb 26, 2025 |
| Feb 24, 2025 | Brian Baranick EVP, GM, Precision Oncology | AGrant or award Restricted Stock Unitsderivative | +28,779 | $0.00 | $0 | 28,779 | Feb 26, 2025 |
| Feb 24, 2025 | James Herriott SVP, General Counsel & Sec | AGrant or award Restricted Stock Unitsderivative | +13,893 | $0.00 | $0 | 13,893 | Feb 26, 2025 |
| Feb 24, 2025 | Jacob A Orville EVP, GM, Screening | AGrant or award Restricted Stock Unitsderivative | +28,779 | $0.00 | $0 | 28,779 | Feb 26, 2025 |
| Feb 24, 2025 | Sarah Condella EVP, Human Resources | AGrant or award Restricted Stock Unitsderivative | +23,817 | $0.00 | $0 | 23,817 | Feb 26, 2025 |
| Feb 25, 2025 | James Herriott SVP, General Counsel & Sec | MOption exercise Restricted Stock Unitsderivative | -1,647 | $0.00 | $0 | 1,648 | Feb 26, 2025 |
| Feb 25, 2025 | Jacob A Orville EVP, GM, Screening | MOption exercise Restricted Stock Unitsderivative | -3,954 | $0.00 | $0 | 3,955 | Feb 26, 2025 |
| Feb 25, 2025 | Brian Baranick EVP, GM, Precision Oncology | MOption exercise Restricted Stock Unitsderivative | -3,954 | $0.00 | $0 | 3,955 | Feb 26, 2025 |
| Feb 25, 2025 | Sarah Condella EVP, Human Resources | MOption exercise Restricted Stock Unitsderivative | -3,954 | $0.00 | $0 | 3,955 | Feb 26, 2025 |
| Feb 24, 2025 | Kevin T Conroy President and CEO | AGrant or award Restricted Stock Unitsderivative | +111,146 | $0.00 | $0 | 111,146 | Feb 26, 2025 |
| Feb 25, 2025 | Kevin T Conroy President and CEO | MOption exercise Restricted Stock Unitsderivative | -13,180 | $0.00 | $0 | 13,181 | Feb 26, 2025 |
| Feb 19, 2025 | Brian Baranick EVP, GM, Precision Oncology | MOption exercise Common Stock | +1,729 | $0.00 | $0 | 14,487 | Feb 21, 2025 |
| Feb 19, 2025 | Jacob A Orville EVP, GM, Screening | MOption exercise Common Stock | +2,248 | $0.00 | $0 | 16,688 | Feb 21, 2025 |
| Feb 19, 2025 | James Herriott SVP, General Counsel & Sec | MOption exercise Common Stock | +865 | $0.00 | $0 | 10,731 | Feb 21, 2025 |
| Feb 19, 2025 | Kevin T Conroy President and CEO | MOption exercise Common Stock | +10,374 | $0.00 | $0 | 1,084,565 | Feb 21, 2025 |
| Feb 19, 2025 | Sarah Condella EVP, Human Resources | MOption exercise Common Stock | +2,248 | $0.00 | $0 | 74,859 | Feb 21, 2025 |
| Feb 19, 2025 | D Scott Coward director | MOption exercise Common Stock | +2,248 | $0.00 | $0 | 52,831 | Feb 21, 2025 |
| Feb 19, 2025 | Jacob A Orville EVP, GM, Screening | FTax withholding Common Stock | -1,086 | $49.63 | $54k | 15,602 | Feb 21, 2025 |
| Feb 19, 2025 | Brian Baranick EVP, GM, Precision Oncology | FTax withholding Common Stock | -968 | $49.63 | $48k | 13,519 | Feb 21, 2025 |
| Feb 19, 2025 | James Herriott SVP, General Counsel & Sec | FTax withholding Common Stock | -433 | $49.63 | $21k | 10,298 | Feb 21, 2025 |
| Feb 19, 2025 | D Scott Coward director | FTax withholding Common Stock | -667 | $49.63 | $33k | 52,164 | Feb 21, 2025 |
| Feb 19, 2025 | Kevin T Conroy President and CEO | FTax withholding Common Stock | -3,271 | $49.63 | $162k | 1,081,294 | Feb 21, 2025 |
| Feb 19, 2025 | Sarah Condella EVP, Human Resources | FTax withholding Common Stock | -1,107 | $49.63 | $55k | 73,752 | Feb 21, 2025 |
| Feb 20, 2025 | James Herriott SVP, General Counsel & Sec | AGrant or award Common Stock | +3,324 | $0.00 | $0 | 13,622 | Feb 21, 2025 |
| Feb 20, 2025 | Jacob A Orville EVP, GM, Screening | AGrant or award Common Stock | +4,805 | $0.00 | $0 | 20,407 | Feb 21, 2025 |
| Feb 20, 2025 | Brian Baranick EVP, GM, Precision Oncology | AGrant or award Common Stock | +4,805 | $0.00 | $0 | 18,324 | Feb 21, 2025 |
| Feb 20, 2025 | Kevin T Conroy President and CEO | AGrant or award Common Stock | +48,044 | $0.00 | $0 | 1,129,338 | Feb 21, 2025 |
| Feb 20, 2025 | Sarah Condella EVP, Human Resources | AGrant or award Common Stock | +4,805 | $0.00 | $0 | 78,557 | Feb 21, 2025 |
| Feb 20, 2025 | James Herriott SVP, General Counsel & Sec | FTax withholding Common Stock | -1,531 | $50.48 | $77k | 12,091 | Feb 21, 2025 |
| Feb 20, 2025 | Brian Baranick EVP, GM, Precision Oncology | FTax withholding Common Stock | -2,437 | $50.48 | $123k | 15,887 | Feb 21, 2025 |
| Feb 20, 2025 | Sarah Condella EVP, Human Resources | FTax withholding Common Stock | -2,214 | $50.48 | $112k | 76,343 | Feb 21, 2025 |
| Feb 19, 2025 | D Scott Coward director | MOption exercise Restricted Stock Unitsderivative | -2,248 | $0.00 | $0 | 0 | Feb 21, 2025 |
| Feb 20, 2025 | Kevin T Conroy President and CEO | FTax withholding Common Stock | -21,140 | $50.48 | $1.1M | 1,108,198 | Feb 21, 2025 |
| Feb 20, 2025 | Jacob A Orville EVP, GM, Screening | FTax withholding Common Stock | -2,225 | $50.48 | $112k | 18,182 | Feb 21, 2025 |
| Feb 19, 2025 | Brian Baranick EVP, GM, Precision Oncology | MOption exercise Restricted Stock Unitsderivative | -1,729 | $0.00 | $0 | 0 | Feb 21, 2025 |
| Feb 19, 2025 | James Herriott SVP, General Counsel & Sec | MOption exercise Restricted Stock Unitsderivative | -865 | $0.00 | $0 | 0 | Feb 21, 2025 |
| Feb 19, 2025 | Jacob A Orville EVP, GM, Screening | MOption exercise Restricted Stock Unitsderivative | -2,248 | $0.00 | $0 | 0 | Feb 21, 2025 |
| Feb 19, 2025 | Sarah Condella EVP, Human Resources | MOption exercise Restricted Stock Unitsderivative | -2,248 | $0.00 | $0 | 0 | Feb 21, 2025 |
| Feb 19, 2025 | Kevin T Conroy President and CEO | MOption exercise Restricted Stock Unitsderivative | -10,374 | $0.00 | $0 | 0 | Feb 21, 2025 |
| Jan 2, 2025 | Kimberly J Popovits director | AGrant or award Common Stock | +6,387 | $0.00 | $0 | 6,387 | Jan 6, 2025 |
| Jun 13, 2024 | Michael J Barber director | AGrant or award Common Stock | +5,939 | $0.00 | $0 | 5,939 | Dec 20, 2024 |
| Jun 13, 2024 | D Scott Coward director | AGrant or award Common Stock | +5,939 | $0.00 | $0 | 50,583 | Dec 20, 2024 |
| Jun 13, 2024 | Paul J Clancy director | AGrant or award Common Stock | +5,939 | $0.00 | $0 | 20,640 | Dec 20, 2024 |
| Jun 13, 2024 | James Edward Doyle director | AGrant or award Common Stock | +5,939 | $0.00 | $0 | 56,049 | Dec 20, 2024 |
| Jun 13, 2024 | Kathleen Sebelius director | AGrant or award Common Stock | +7,672 | $0.00 | $0 | 32,671 | Dec 20, 2024 |
| Jun 13, 2024 | Shacey Petrovic director | AGrant or award Common Stock | +5,939 | $0.00 | $0 | 16,406 | Dec 20, 2024 |
| Jun 13, 2024 | Daniel J Levangie director | AGrant or award Common Stock | +5,939 | $0.00 | $0 | 28,914 | Dec 20, 2024 |
| Jun 13, 2024 | Katherine S Zanotti director | AGrant or award Common Stock | +5,939 | $0.00 | $0 | 70,568 | Dec 20, 2024 |
| Nov 13, 2024 | Kevin T Conroy President and CEO | POpen-market purchase Common Stock | +19,500 | $51.35 | $1.0M | 1,074,191 | Nov 13, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Brian BaranickEVP, GM, Precision Oncology
- Michael J Barberdirector
- Aaron BloomerEVP, Chief Financial Officer
- D Scott Cowarddirector
- Paul J Clancydirector
- Sarah CondellaEVP, Human Resources
- Kevin T ConroyPresident and CEO
- James Edward Doyledirector
- James HerriottSVP, General Counsel & Sec
- Daniel J Levangiedirector
- Jacob A OrvilleEVP, GM, Screening
- Shacey Petrovicdirector
- Kimberly J Popovitsdirector
- Kathleen Sebeliusdirector
- Katherine S Zanottidirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.